Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes | Zendy

Satish K. Garg | Zendy; Robert R. Henry | Zendy; Phillip Banks | Zendy; John B. Buse | Zendy; Melanie J. Davies | Zendy; Gregory Fulcher | Zendy; Paolo Pozzilli | Zendy; Diane GestyPalmer | Zendy; Pablo Lapuerta | Zendy; Rafael Simó | Zendy; Thomas Danne | Zendy; Darren K. McGuire | Zendy; Jake A. Kushner | Zendy; Anne L. Peters | Zendy; Paul Strumph | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

Author(s) -

Satish K. Garg,

Robert R. Henry,

Phillip Banks,

John B. Buse,

Melanie J. Davies,

Gregory Fulcher,

Paolo Pozzilli,

Diane GestyPalmer,

Pablo Lapuerta,

Rafael Simó,

Thomas Danne,

Darren K. McGuire,

Jake A. Kushner,

Anne L. Peters,

Paul Strumph

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1708337

Subject(s) - medicine , hypoglycemia , glycated hemoglobin , placebo , insulin , diabetes mellitus , diabetic ketoacidosis , blood pressure , type 2 diabetes , gastroenterology , bolus (digestion) , type 1 diabetes , randomization , glycemic , ketoacidosis , clinical endpoint , endocrinology , randomized controlled trial , pathology , alternative medicine

In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research